Advertisement
Australia markets closed
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • AUD/USD

    0.6424
    -0.0001 (-0.02%)
     
  • OIL

    82.23
    -0.50 (-0.60%)
     
  • GOLD

    2,396.80
    -1.20 (-0.05%)
     
  • Bitcoin AUD

    101,479.16
    +5,185.05 (+5.38%)
     
  • CMC Crypto 200

    1,343.04
    +30.42 (+2.37%)
     
  • AUD/EUR

    0.6020
    -0.0011 (-0.18%)
     
  • AUD/NZD

    1.0890
    +0.0015 (+0.14%)
     
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     
  • FTSE

    7,840.42
    -36.63 (-0.47%)
     
  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     
  • DAX

    17,743.37
    -94.03 (-0.53%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Global RNA-based Therapeutics and Vaccines Market Trajectory & Analytics Report 2021-2027

Dublin, May 11, 2021 (GLOBE NEWSWIRE) -- The "RNA-based Therapeutics and Vaccines - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global RNA-based Therapeutics and Vaccines Market to Reach $499 Million by 2027

Amid the COVID-19 crisis, the global market for RNA-based Therapeutics and Vaccines estimated at US$14.7 Million in the year 2020, is projected to reach a revised size of US$499 Million by 2027, growing at a CAGR of 65.5% over the period 2020-2027.

RNA-based Therapeutics, one of the segments analyzed in the report, is projected to record 68.1% CAGR and reach US$372.5 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the RNA-based Vaccines segment is readjusted to a revised 59.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $4.5 Million, While China is Forecast to Grow at 62% CAGR

The RNA-based Therapeutics and Vaccines market in the U.S. is estimated at US$4.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$76.6 Million by the year 2027 trailing a CAGR of 62% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 59.2% and 55.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 43.7% CAGR.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights

  • World Market Trajectories

  • Impact of Covid-19 and a Looming Global Recession

ADVERTISEMENT

2. FOCUS ON SELECT PLAYERS(Total 41 Featured):

  • Alnylam Pharmaceuticals, Inc.

  • Arbutus Biopharma Corporation

  • Arrowhead Pharmaceuticals, Inc.

  • BioNTech AG

  • CureVac AG

  • Dicerna Pharmaceuticals, Inc.

  • Marina Biotech, Inc.

  • miRagen Therapeutics, Inc.

  • Moderna, Inc.

  • Quark Pharmaceuticals, Inc.

  • Regulus Therapeutics, Inc.

  • Sylentis S.A.

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

  • World Current & Future Analysis for RNA-based Therapeutics and Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

  • World Current & Future Analysis for RNA-based Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

  • World Current & Future Analysis for RNA-based Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

  • World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

  • World Current & Future Analysis for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

  • World Current & Future Analysis for Ophthalmology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

  • World Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

  • World Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

  • World Current & Future Analysis for Genetic Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

III. GEOGRAPHIC MARKET ANALYSIS

IV. COMPETITION

  • Total Companies Profiled: 41

For more information about this report visit https://www.researchandmarkets.com/r/z3902r

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900